Q-omics provides the consensus-scored TRHR profile across patient tissues and cancer cell-line models. TRHR expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TRHR is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, TRHR RNA expression shows 8,622 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight SCLC, THCA, and LAML as cancer lineages where TRHR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRHR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRHR survival associations across molecular data types. TRHR RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRHR RNA expression–survival associations across cancer types. High TRHR expression shows unfavorable associations in UCEC, LGG, THYM, UVM and READ, but favorable associations in SCLC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify SCLC as the clearest survival context for TRHR RNA expression.
This table summarizes TRHR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRHR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRHR shows lower tumor expression in BRCA and COAD and higher tumor expression in THCA, LUSC and KIRC. The THCA box plot shows higher TRHR RNA expression in tumor versus normal tissue (log2 FC = +0.359, t-test p < 0.001).
This table shows molecular features associated with TRHR in patient tissues and cancer cell lines. In patient samples, TRHR shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, TRHR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
